• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS INC. ECRE_2 REAGENTS (4 X 350 TESTS) - ENZ; ADVIA 2400 - ENZYMATIC CREATININE 2 (ECRE_2)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS INC. ECRE_2 REAGENTS (4 X 350 TESTS) - ENZ; ADVIA 2400 - ENZYMATIC CREATININE 2 (ECRE_2) Back to Search Results
Model Number ADVIA 2400 - ENZYMATIC CREATININE 2 (ECRE_2)
Medical Device Problem Code Low Test Results (2458)
Health Effect - Clinical Code No Known Impact Or Consequence To Patient (2692)
Date of Event 10/15/2018
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
Siemens healthcare diagnostics has become aware of the potential of falsely depressed creatinine results for patients undergoing phenindione therapy when using the enzymatic methodology.Advia ecre_2 results on a patients' samples showed interference with the phenindione drug and/or its metabolites.The atellica ch ecre_2 assay uses the same reagents, calibrators, and assay condition as advia ecre_2, and is expected to show a similar negative interference in samples from patients on phenindione therapy.It is also expected that the dimension and dimension vista enzymatic assays would be impacted in a similar way.The instructions for use (ifus) for the siemens advia, atellica ch, dimension and dimension vista enzymatic creatinine assays will be updated to reflect this information.An urgent medical device correction (umdc) achc20-01.A.Us.Chc was sent to advia chemistry us enzymatic creatinine customers and an urgent field safety notice (ufsn) achc20-01.A.Ous.Chc was sent to advia chemistry ous enzymatic creatinine customers in december 2019.An urgent medical device correction (umdc) achc20-01.A.Us.Dm was sent to dimension clinical chemistry us enzymatic creatinine customers and an urgent field safety notice (ufsn) achc20-01.A.Ous.Dm was sent to dimension clinical chemistry ous enzymatic creatinine customers in december 2019.An urgent medical device correction (umdc) achc20-01.A.Us.Dv was sent to dimension vista us enzymatic creatinine customers and an urgent field safety notice (ufsn) achc20-01.A.Ous.Dv was sent to dimension vista ous enzymatic creatinine customers in december 2019.The umdc and ufsn advise customers the "limitations of the procedure" section of the instructions for use (ifu) for the advia chemistry ecre_2 assay, dimension ezcr assay and the dimension vista ecrea assay will be updated to indicate that 'use of this assay is not recommended for patients undergoing treatment with phenindione, due to the potential for falsely depressed results'.An urgent medical device correction (umdc) achc20-01.A.Us was sent to atellica chemistry us enzymatic creatinine customers and an urgent field safety notice (ufsn) achc20-01.A.Ous was sent to atellica chemistry ous enzymatic creatinine customers in december 2019.The umdc and ufsn advise customers that the "limitations" section of the instructions for use (ifu) for the atellica ecre_2 assay will be updated to indicate that 'use of this assay is not recommended for patients undergoing treatment with phenindione, due to the potential for falsely depressed results'.Mdr 2432235-2019-00456, mdr 2432235-2019-00457, and mdr 2432235-2019-00459 were filed for the same event.Mdr 2432235-2019-00460 was filed for a similar event from the same customer.
 
Event or Problem Description
One discordant, falsely depressed enzymatic creatinine 2 (ecre_2) result was obtained on a single patient using advia 2400 analyzer.The initial result was reported to the physician(s).Additional samples from the same patient were repeated using advia 2400 analyzer and two alternate non-siemens methods.The repeat results using the 2 alternate non-siemens methods were considered correct and reported to the physician(s).There are no known reports of patient intervention or adverse health consequences due to the discordant, falsely depressed ecre_2 results.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ECRE_2 REAGENTS (4 X 350 TESTS) - ENZ
Common Device Name
ADVIA 2400 - ENZYMATIC CREATININE 2 (ECRE_2)
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS INC.
511 benedict avenue
tarrytown NY 10591
MDR Report Key9495094
Report Number2432235-2019-00458
Device Sequence Number1877947
Product Code JFY
UDI-Device Identifier00630414526690
UDI-Public00630414526690
Combination Product (Y/N)N
Initial Reporter CountryUK
PMA/510(K) Number
K070727
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source foreign,health professional,u
Initial Reporter Occupation Other Health Care Professional
Remedial Action Recall
Type of Report Initial
Report Date (Section B) 12/19/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model NumberADVIA 2400 - ENZYMATIC CREATININE 2 (ECRE_2)
Device Catalogue Number10335869
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Type of Report(Section G)Initial
Initial Date Received by Manufacturer 12/16/2019
Initial Report FDA Received Date12/19/2019
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
If action reported to FDA under 21 USC 360i(g), list
FDA-assigned Recall Number or include a statement
2432235-12/19/2019-007-C
Patient Sequence Number1
-
-